Baird Financial Group Inc. Buys 1,179 Shares of GSK PLC Sponsored ADR $GSK

Baird Financial Group Inc. boosted its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 5.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,790 shares of the pharmaceutical company’s stock after acquiring an additional 1,179 shares during the quarter. Baird Financial Group Inc.’s holdings in GSK were worth $960,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Vident Advisory LLC raised its stake in GSK by 41.3% during the first quarter. Vident Advisory LLC now owns 28,374 shares of the pharmaceutical company’s stock worth $1,099,000 after acquiring an additional 8,294 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new position in shares of GSK in the 1st quarter worth approximately $2,948,000. Transamerica Financial Advisors LLC grew its position in GSK by 104.8% during the 1st quarter. Transamerica Financial Advisors LLC now owns 3,602 shares of the pharmaceutical company’s stock worth $140,000 after acquiring an additional 1,843 shares during the last quarter. Ieq Capital LLC grew its position in GSK by 17.7% during the 1st quarter. Ieq Capital LLC now owns 11,260 shares of the pharmaceutical company’s stock worth $436,000 after acquiring an additional 1,693 shares during the last quarter. Finally, CreativeOne Wealth LLC bought a new stake in GSK during the 1st quarter worth approximately $205,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently commented on GSK. Wall Street Zen upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 5th. Berenberg Bank restated a “hold” rating on shares of GSK in a research report on Tuesday, June 3rd. Six investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, GSK currently has an average rating of “Reduce” and a consensus price target of $37.38.

GSK Stock Performance

Shares of GSK stock opened at $40.88 on Wednesday. The firm has a fifty day moving average of $38.59 and a two-hundred day moving average of $38.40. The stock has a market capitalization of $83.26 billion, a price-to-earnings ratio of 18.93, a PEG ratio of 2.00 and a beta of 0.53. GSK PLC Sponsored ADR has a 52 week low of $31.72 and a 52 week high of $44.19. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The company had revenue of $10.64 billion during the quarter, compared to analysts’ expectations of $7.92 billion. During the same quarter in the previous year, the company posted $0.43 EPS. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, equities research analysts predict that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be issued a $0.4206 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 4.1%. GSK’s payout ratio is 77.78%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.